Psilera, Alcohol Use Disorder, AUD, NIH Grant, NIAAA, SBIR Program, Neuroplastogens, Non-Hallucinogenic Psychedelics, Psilocybin Derivatives, Addiction Research, Preclinical Research

Tampa, Florida, U.S., October 8, 2026 Psilera Inc., a biopharmaceutical company developing next-generation neuroplastogens and psychedelic-inspired therapies, has announced...